CN219049602U

CN219049602U - Microneedle patch

Info

Publication number: CN219049602U
Application number: CN202222790669.8U
Authority: CN
Inventors: 张晓茹; 陈晓晴; 王小龙; 陈佩岚; 黄彬彬
Original assignee: Guangdong Ruicheng Medical Technology Co ltd; Zhongke Ruiji Shenzhen Medical Technology Co ltd
Current assignee: Guangdong Ruicheng Medical Technology Co ltd; Zhongke Ruiji Haining Biotechnology Co ltd
Priority date: 2022-10-21
Filing date: 2022-10-21
Publication date: 2023-05-23
Anticipated expiration: 2032-10-21

Abstract

The utility model relates to the technical field of microneedle administration hair growth, in particular to a microneedle patch. The microneedle patch is used for giving out medicines. The microneedle patch comprises a base and a plurality of needle bodies, wherein the base is made of soluble high polymers, the needle bodies are arranged on one side surface of the base in an array mode, each needle body comprises a connecting portion connected with the base and a medicine carrying portion located at one end, far away from the base, of the connecting portion, and the connecting portion and the medicine carrying portion are different in material. The medicine carrying part is composed of an exosome, and is positioned at the tip end part of the needle body, medicine carrying is carried through the micro needle tip end of the micro needle patch, so that the acting medicine can be completely and directly contacted with a human body when the micro needle is used for medicine administration, the exosome is enabled to be distributed at the needle tip part in a concentrated mode through the arrangement of the medicine carrying part, medicine release efficiency is improved because medicine is slowly released after external wrappers do not need to be dissolved, the exosome in the micro needle patch can be dissolved fast, hair regeneration is obviously promoted, and the technical problem that the medicine release efficiency of the existing micro needle hair growing technology is low is effectively solved.

Description

Microneedle patch

Technical Field

The utility model relates to the technical field of microneedle administration hair growth, in particular to a microneedle patch.

Background

The hair growth cycle is a dynamic cycle and can be divided into three phases including a growing phase, a catagen phase and a telogen phase. It is divided into that for normal people, 85% -90% of hair is in growing period and 1% of hair is in withdrawing period. But 30% of patients with alopecia are in rest. When a large amount of hair is in the hair-backing period, the hair follicle is dormant, and the hair cannot grow, so that alopecia is caused. There are many types of alopecia, hereditary alopecia, chemical alopecia, nutritional alopecia, etc., in which hereditary alopecia, that is, androgenic alopecia, is a relatively common type, minoxidil tincture for external application, and finasteride or dutasteride for oral administration are often used for the treatment of androgenic alopecia, but unavoidable side effects are brought about. The side effects of drug treatment are more, and the introduction of new treatment methods is particularly necessary.

The traditional hair growth technology is used for administration by subcutaneous injection, mesoderm therapy, etc. In order to achieve therapeutic effect, a skin-breaking treatment is necessary. The skin-breaking treatment produces a strong pain sensation and is also extremely sensitive to allergy. The micro needle can pierce the epidermis layer to enter the dermis layer and form micro channels on the skin surface to help the medicine to enter the skin, the length of the micro needle is insufficient to touch the subcutaneous pain nerve, and the formed micro channels can be recovered within a plurality of hours, so that the micro-invasive skin care device has micro-invasive and convenient use. The existing action medicament of a plurality of microneedles is wrapped in the middle of a polymer material, when the microneedles are used for drug delivery, after the microneedles are injected, the human body is required to dissolve the polymer material wrapped outside the action medicament, then the action medicament can be released, the release is slow or incomplete, and the treatment effect is required to be improved.

Disclosure of Invention

The utility model mainly aims to provide a microneedle patch, which aims to solve the technical problem that the medicament release efficiency of the existing microneedle hair growth technology is low.

In order to achieve the above object, the present utility model provides a microneedle patch for dispensing drugs, the microneedle patch comprising:

the base is a soluble high polymer;

the needle body comprises a connecting portion and a medicine carrying portion, wherein the connecting portion is connected with the medicine carrying portion, the material of the connecting portion is different from that of the medicine carrying portion, the connecting portion is connected with the base, the medicine carrying portion is arranged at one end of the connecting portion opposite to the base, and the medicine carrying portion is provided with an exosome.

Optionally, the needle body has a needle height direction perpendicular to the base, the duty ratio of the medicine carrying part relative to the needle body is A, and the value range of A is 1/4-A < 1.

Optionally, the height ratio of the medicine carrying part to the connecting part along the needle height direction is 1:1;

and/or, along the height direction of the needle, the height of the needle body is 800-850 mu m;

and/or the interval between the two needle bodies is 400-500 μm;

and/or the needle bodies are arranged in an array of ten times ten.

Optionally, the needle body tapers in cross-sectional area from an end adjacent the base to an end distal from the base;

and/or the connection part of the connection part and the medicine carrying part is in smooth transition.

Optionally, the needle body is conical, and a diameter of one end of the connecting part, which is far away from the medicine carrying part, is 200-250 μm.

Optionally, the needle body is in a triangular pyramid shape, and the unilateral length of the connecting part away from one end of the medicine carrying part is 180-200 μm.

Optionally, two adjacent needle bodies in the same row or the same column are arranged in a staggered manner, so that two side edges of the two adjacent needle bodies, which are close to each other, are arranged in parallel.

Optionally, the base is the same composition as the connection;

and/or the base and the connecting part are arranged in an integrated structure;

and/or the connecting part and the medicine carrying part are arranged in an integrated structure.

Optionally, the soluble polymer comprises one of polyvinyl alcohol, polycaprolactone, polyvinylpyrrolidone, hyaluronic acid, chitosan, carboxymethyl cellulose, and fibroin.

Optionally, the base is sodium hyaluronate;

and/or the connecting part is sodium hyaluronate.

According to the technical scheme, medicine is carried through the micro-needle tip of the micro-needle patch, and the technical problem that the medicine release efficiency of the existing micro-needle hair growing technology is low is solved. The microneedle patch is used for giving out medicines. The microneedle patch comprises a base and a plurality of needle bodies, wherein the base is made of soluble high polymers, the needle bodies are arranged on one side surface of the base in an array mode, each needle body comprises a connecting portion connected with the base and a medicine carrying portion located at one end, far away from the base, of the connecting portion, and the connecting portion and the medicine carrying portion are different in material. The medicine carrying part is composed of an exosome and is positioned at the tip end part of the needle body, the medicine can be completely contacted with a human body when the micro-needle is used for medicine administration, and the medicine carrying part is arranged to enable the exosome medicine to be intensively distributed at the needle end part, so that the medicine is slowly released after external wrappers are not required to be dissolved, the medicine release efficiency is improved, the exosome in the micro-needle patch can be quickly dissolved, the hair regeneration is effectively promoted, and the technical problem of low medicine release efficiency of the existing micro-needle hair growing technology is effectively solved.

Drawings

In order to more clearly illustrate the embodiments of the present utility model or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, and it is obvious that the drawings in the following description are only some embodiments of the present utility model, and other drawings may be obtained according to the structures shown in these drawings without inventive effort for a person skilled in the art.

FIG. 1 is a schematic diagram of a microneedle patch according to one embodiment of the present utility model;

FIG. 2 is a schematic view of a partial size configuration of one embodiment of a microneedle patch of the present utility model;

FIG. 3 is a schematic structural view of another embodiment of a microneedle patch of the present utility model;

fig. 4 is a schematic diagram of a partial enlarged structure of a Q portion of the embodiment of fig. 3.

Reference numerals illustrate:

reference numerals	Name of the name	Reference numerals	Name of the name	Reference numerals	Name of the name
						10	Base seat	30	Needle body	31	Connecting part
11	Backing lining	12	Support part	32	Medicine carrying part
						D	Diameter of	H	Microneedle height	L	Spacing of
100	Microneedle patch	50	Mould

The achievement of the objects, functional features and advantages of the present utility model will be further described with reference to the accompanying drawings, in conjunction with the embodiments.

Detailed Description

The following description of the embodiments of the present utility model will be made clearly and fully with reference to the accompanying drawings, in which it is evident that the embodiments described are only some, but not all embodiments of the utility model. All other embodiments, which can be made by those skilled in the art based on the embodiments of the utility model without making any inventive effort, are intended to be within the scope of the utility model.

It should be noted that all directional indicators (such as up, down, left, right, front, and rear … …) in the embodiments of the present utility model are merely used to explain the relative positional relationship, movement, etc. between the components in a particular posture (as shown in the drawings), and if the particular posture is changed, the directional indicator is changed accordingly.

In the present utility model, unless specifically stated and limited otherwise, the terms "connected," "affixed," and the like are to be construed broadly, and for example, "affixed" may be a fixed connection, a removable connection, or an integral body; can be mechanically or electrically connected; either directly or indirectly, through intermediaries, or both, may be in communication with each other or in interaction with each other, unless expressly defined otherwise. The specific meaning of the above terms in the present utility model can be understood by those of ordinary skill in the art according to the specific circumstances.

Furthermore, descriptions such as those referred to as "first," "second," and the like, are provided for descriptive purposes only and are not to be construed as indicating or implying a relative importance or implying an order of magnitude of the indicated technical features in the present disclosure. Thus, a feature defining "a first" or "a second" may explicitly or implicitly include at least one such feature. In addition, the meaning of "and/or" as it appears throughout is meant to include three side-by-side schemes, for example, "a and/or B", including a scheme, or B scheme, or a scheme that is satisfied by both a and B. In addition, the technical solutions of the embodiments may be combined with each other, but it is necessary to base that the technical solutions can be realized by those skilled in the art, and when the technical solutions are contradictory or cannot be realized, the combination of the technical solutions should be considered to be absent and not within the scope of protection claimed in the present utility model.

The present utility model proposes a microneedle patch 100.

Referring to fig. 1 to 4, fig. 1 is a schematic structural view of an embodiment of a microneedle patch 100 according to the present utility model; FIG. 2 is a schematic view of a partial size configuration of an embodiment of a microneedle patch 100 according to the present utility model; fig. 3 is a schematic structural view of another embodiment of a microneedle patch 100 according to the present utility model; fig. 4 is a schematic diagram of a partial enlarged structure of a Q portion of the embodiment of fig. 3.

In an embodiment of the present utility model, the microneedle patch is used for dispensing medicines, and the microneedle patch 100 includes a base 10 and a plurality of needle bodies 30; as shown in fig. 1 and 2, the base 10 is a soluble polymer; the plurality of needle bodies 30 are arranged on one side surface of the base 10 in an array manner, each needle body 30 comprises a connecting portion 31 and a medicine carrying portion 32 which are connected, the connecting portion 31 and the medicine carrying portion 32 are different in material, the connecting portion 31 is connected with the base 10, the medicine carrying portion 32 is arranged at one end, opposite to the base 10, of the connecting portion 31, and the medicine carrying portion 32 is provided with an exosome.

According to the technical scheme, medicine is carried through the micro needle tip of the micro needle patch 100, so that the technical problem of low medicine release efficiency of the existing micro needle hair generating technology is solved. The microneedle patch 100 is used for dispensing drugs. The microneedle patch 100 comprises a base 10 made of a soluble polymer and a plurality of needle bodies 30, wherein the plurality of needle bodies 30 are arranged on one side surface of the base 10 in an array manner, each needle body 30 comprises a connecting portion 31 connected with the base 10 and a medicine carrying portion 32 located at one end, far away from the base 10, of the connecting portion 31, and the connecting portion 31 and the medicine carrying portion 32 are different in material. The medicine carrying part 32 is provided with an exosome, the setting position of the medicine carrying part 32 is positioned at the tip end part of the needle body 10, the medicine can be completely contacted with a human body when the micro-needle is used for medicine administration, and the medicine carrying part 32 is arranged to enable the exosome medicine to be intensively distributed at the needle end part, so that the medicine is not required to be slowly released after the external wrapping material is dissolved, the medicine release efficiency is improved, and the technical problem of low medicine release efficiency of the existing micro-needle hair growing technology is effectively solved.

Further, the base 10 includes a backing 11 and a supporting portion 12, the backing 11 is connected with the connecting portion 31, the supporting portion 12 is disposed on a side of the backing 11 far away from the connecting portion 31, wherein a cross-sectional area of the supporting portion 12 is larger than that of the backing 11, so that the microneedle patch 100 can make the needle body 30 go deeper into the skin by pressing the periphery and the middle of the supporting portion 12, the supporting portion 12 strengthens a supporting function of the backing 11, but a height superposition of the two cannot trigger pain nerves, the supporting portion 12 is pressed when the backing 11 is tightly attached to the skin, so that after the needle body 30 is inserted into the dermis layer, a target substance (exosome) enters the dermis layer along with dissolution of a polymer material and spreads out in the dermis layer, and finally is absorbed by a local skin attachment.

It is understood that the acting agent of the present utility model is an exosome, and the principle of the exosome is to promote hair follicle to enter the anagen phase by activating hair follicle stem cells in the telogen phase. The exosomes can avoid taking blood samples by themselves while guaranteeing the rejection, and the cost is greatly reduced. The exosome is loaded in the HA solution, the HA solution is sodium hyaluronate solution, the HA solution is a beneficial substance which can be absorbed by human body, and compared with chemical agents, the HA solution HAs no side effect, and is easy to be actively absorbed by human body, so that the exosome is convenient to release and act on the dermis layer of the human body.

Alternatively, the ratio of the medicine carrying portion 32 to the needle body 30 is A, and the value of A is 1/4.ltoreq.A < 1.

In this embodiment, the arrangement of the medicine carrying portion 32 improves the stability and effectiveness of the action medicine, the ratio of the medicine carrying portion 32 to the needle body 30 is in a certain range, the ratio of the medicine carrying portion 32 to the needle body 30 is set to be A, and the value range of A is 1/4-A < 1. The drug delivery portion 32 is located at the needle tip portion, and has a small volume itself, and in order to ensure that each microneedle patch 100 has a sufficient drug delivery capacity, the drug delivery portion 32 needs to occupy a sufficient volume of the needle body 30. The a may be a volume ratio of the medicine carrying portion 32 to the needle body 30, or a length ratio of the medicine carrying portion 32 to the needle body 30 in the longitudinal extension direction of the needle. The microneedle administration needs to promote the release completeness and the action completeness of the action medicament, so that the proportion of the medicament carrying part 32 occupying the needle body 30 is smaller than that of the whole needle body 30, so that the medicament carrying the exosome can completely enter the dermis of the human body without exposing outside the skin, and the waste of the action medicament caused by the fact that the exosome is not acted on the dermis of the human body is avoided.

Furthermore, the value range of A is preferably 1/2-2 and 2/3, so that the sufficient acting medicine amount is ensured, and the exosome can be ensured to completely act on the skin comprising the epidermis layer, the dermis layer and the skin between the epidermis layer and the dermis layer of the human body, and the waste of the acting medicine is avoided.

Optionally, the needle body 30 has a needle height direction perpendicular to the base 10; the ratio of the heights of the medicine carrying portion 32 and the connecting portion 31 in the needle height direction is 1:1.

In this embodiment, the needle body 30 is provided with a needle tip and a needle root, and the direction from the needle tip to the needle root is the needle height direction of the needle body 30, and the medicine carrying portion 32 is located at the needle tip portion of the needle body 30, so that the needle tip portion can extend completely into the dermis layer of the human body when the needle body 30 is administered, so that the acting medicine is released completely, and the acting medicine can also exert completely. The medicine carrying capacity of the medicine carrying part 32 is determined by the area of the needle root, the total microneedle height H of the needle body 10 and the height ratio of the medicine carrying part 32 to the connecting part 31 along the needle height direction, wherein the height ratio of the medicine carrying part 32 to the connecting part 31 along the needle height direction is 1:1, namely, the height of the medicine carrying part 32 is the same as the height of the connecting part 31 along the needle height direction, and the arrangement of the connecting part 31 strengthens the connection and structural support relationship between the backing 11 of the base 10 and the medicine carrying part 32, thereby improving the release efficiency of the exosome of the medicine carrying part 32.

Alternatively, the needle bodies 30 are arranged in an array of ten times ten. The microneedle height H of the needle body 30 is 800-850 μm along the needle height direction; the distance L between the two needle bodies 30 is 400 μm to 500 μm.

In this embodiment, the needle bodies 30 are arranged in an array to form a microneedle patch, and a distance L of about half the height of each two adjacent needle bodies 30 is provided between each two adjacent needle bodies 30, so that each needle body 30 can penetrate into the skin of a human body when the microneedle is used for applying a needle, and the two needle bodies 30 cannot affect each other. The microneedle height H of the needle body 30 determines the depth to which the microneedle patch 100 can penetrate the skin, preferably, the microneedle height H of the needle body 30 is 800 μm to 850 μm, and the height of the drug loading part 32 is 450 μm to 700 μm, so that the HA solution containing the exosomes can be stably disposed at the tip end of the needle body 30, and the HA solution can be absorbed by the human body, thereby reducing the damage of the chemical agent to the human body, and improving the preservation and release stability of the exosomes.

It will be appreciated that the preparation of the microneedle patch 100 is accomplished by a mold process. The main components of the drug carrier 32 are exosomes and HA solution. In one process of manufacturing the microneedle patch 100, the drug-carrying portion 32 is a completely mixed solution directly prepared from a mixed solution of an exosome and HA by directly placing the mixed solution of the exosome and HA into a mold to form the drug-carrying portion 32.

In another embodiment, before the mixed solution of the exosome and the HA is put into the mold, a thin layer of HA solution is coated on the surface of the mold, and then the mixed solution of the exosome and the HA is put into the mold to form the drug carrying part 32, the drug carrying part 32 is a mixed drug carrying part of a layer of film wrapped by the mixed solution of the exosome and the HA, the mixed solution of the exosome and the HA is completely mixed, and the coating of the HA solution on the surface of the mold can effectively reduce the waste of the acting medicament caused by the contamination of the exosome to the mold in the preparation process, and simultaneously can also effectively maintain the activity of the exosome.

When the microneedle patch 100 is applied to a human body, the HA solution wrapped on the outer layer can be quickly absorbed by the human body, and exosomes can be completely and actively preserved and completely released to the dermis layer of the human body, so that the activity of an acting medicament is improved, and compared with other microneedles wrapped in the middle of a core, the microneedle patch 100 disclosed by the utility model HAs the advantages of higher solubility, and better release speed and preservation integrity of the exosomes.

In another possible embodiment, the mixed liquid with higher concentration of exosomes dissolved in HA solution is coated outside the needle tip manufactured by the mold, and then the mixed liquid is dried to form the microneedle patch 100, and the drug carrying part 32 wraps the needle tip part with higher volume of exosomes and mixed solution for the mixed solution of the higher concentration of exosomes and HA, so that the concentration of exosomes in the drug carrying part 32 is increased, the concentration and the speed of exosomes released by the drug carrying part 32 are increased, the release time of the exosomes with higher concentration is advanced, and the effectiveness of microneedle drug application is improved.

Alternatively, the cross-sectional area of the needle body 30 gradually decreases from the end adjacent to the base 10 to the end distant from the base 10, and the junction of the connecting portion 31 and the medicine carrying portion 32 is smoothly transitioned.

In this embodiment, the preparation of the microneedle patch 100 is accomplished by a mold method. In the molding process, the joint of the medicine carrying part 32 and the connecting part 31 is positioned on the outer circumferential surface of the pin hole of the mold, so that the joint of the medicine carrying part 32 and the connecting part 31 can be smoothly transited in the molding process, saw teeth, cracks or faults are not generated, and the joint strength of the joint of the medicine carrying part 32 and the connecting part 31 is increased. Also, the cross-sectional area of the molded needle body 30 gradually decreases from the end adjacent to the base 10 to the end distant from the base 10, so that the side of the needle body 30 facing away from the base 10 can have a pointed shape, facilitating Shi Zhen.

Alternatively, the needle body 30 has a conical shape, and the diameter D of the end of the connecting portion 31 remote from the drug carrying portion 32 is 200 μm to 250 μm.

As shown in fig. 3 and 4, alternatively, the needle body 30 may have a triangular pyramid shape, and the connecting portion 31 may have a single-side length of 180 μm to 200 μm at an end thereof remote from the drug carrying portion 32.

In this embodiment, the shape of the needle body 30 of the microneedle patch 100 is conical, triangular pyramid, or other tapered shapes with a tip, wherein when the needle body 30 is conical, the bottom area of the cone is the cross-sectional area of the needle root, the diameter D of the bottom surface of the cone is 200 μm to 250 μm, and the distance L between the two needle bodies 30 is 400 μm to 500 μm, so that the overall side length of the microneedle patch is between 6mm and 7.5 mm. When the needle body 30 is in a triangular pyramid shape, the bottom area of the triangular pyramid is the cross-sectional area of the needle root, the side length of the bottom surface of the triangular pyramid is 180-200 μm, and the distance L between the two needle bodies 30 is 400-500 μm, so that the whole side length of the microneedle patch is 5.8-7 mm. The microneedle patch 100 formed by the two different types of needle bodies 30 has a small surface area, which can be regarded as a small finger nail cover size, and the microneedle patch 100 can be directly applied by a user to reduce the hair generating cost of the user.

Optionally, when the needle body 30 is in a triangular pyramid shape, two adjacent needle bodies 30 in the same row or the same column are arranged in a staggered manner, so that two side edges of the two adjacent needle bodies 30, which are close to each other, are arranged in parallel, the arrangement density of the needle bodies 30 can be effectively improved, the arrangement area of the microneedle patch 100 is reduced, and the trauma caused to the human body by the microneedle application is reduced.

Alternatively, the base 10 is of the same composition as the connecting portion 31.

In the present embodiment, the support portion 12 of the base 10 is different in size and thickness from the backing 11, but the components of the two are the same, and the support portion 12 and the backing 11 are provided as an integrally molded structure. The base 10 and the connecting portion 31 have the same composition, that is, the supporting portion 12, the backing 11 and the connecting portion 31 have the same composition, so that the supporting portion 12, the backing 11 and the connecting portion 31 have stronger connection tightness.

Optionally, the soluble polymer comprises one of polyvinyl alcohol, polycaprolactone, polyvinylpyrrolidone, hyaluronic acid, chitosan, carboxymethyl cellulose and fibroin, and has good biocompatibility, and can be absorbed by human body more easily when used as a drug-carrying solvent and a seat body, so that the smoothness of releasing and acting the acting medicament is improved. The adoption of a single soluble high polymer reduces the biological stimulation of the soluble high polymer to human bodies.

Alternatively, the base 10 and the connecting portion 31 are integrally formed, and in one embodiment, the connecting portion 31 and the drug loading portion 32 are integrally formed.

In this embodiment, the preparation of the microneedle patch 100 prepares the drug-carrying portion 32, the connection portion 31, the backing 11, and the supporting portion 12 by a mold, wherein the connection portion 31, the backing 11, and the supporting portion 12 may be made of the same material and are different from the drug-carrying portion 32. In the product molding, the connecting portion 31, the backing 11 and the supporting portion 12 may be made of a solution of the same substance, and the drug carrying portion 32 contains an exosome which forms an action drug for promoting hair regeneration, thereby realizing the reliability and effectiveness of the microneedle application.

Further, the connection portion 31 and the drug carrying portion 32 are integrally configured, wherein a drug carrying solvent used as an exosome in the drug carrying portion 32 can be the same as a component of the connection portion 31, and compatibility and connection tightness between components in a product molding process can be effectively improved.

Further, the base 10 is sodium hyaluronate, the connecting portion 31 is sodium hyaluronate, and the drug-carrying solvent used as the exosome in the drug-carrying portion 32 is sodium hyaluronate, so that sodium hyaluronate made of the same material is easier to form a compact and stable product structure in molding, and has good compatibility, no harm and easy absorption by human bodies.

The foregoing description of the preferred embodiments of the present utility model should not be construed as limiting the scope of the utility model, but rather should be understood to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the utility model as defined by the following description and drawings or any application directly or indirectly to other relevant art(s).

Claims

1. A microneedle patch for dispensing a medicament, the microneedle patch comprising:

the base is a soluble high polymer;

2. The microneedle patch of claim 1, wherein the drug carrier has a duty ratio a with respect to the needle body, and wherein a has a value in the range of 1/4.ltoreq.a < 1.

3. The microneedle patch of claim 2, wherein the needle body has a needle height direction perpendicular to the base;

the height ratio of the medicine carrying part to the connecting part along the needle height direction is 1:1;

and/or the interval between the two needle bodies is 400-500 μm;

and/or the needle bodies are arranged in an array of ten times ten.

4. The microneedle patch of claim 1, wherein the needle body tapers in cross-sectional area from an end adjacent the base to an end distal from the base;

5. The microneedle patch of claim 1, wherein the needle body is conical, and the diameter of the end of the connecting portion remote from the drug carrying portion is 200 μm to 250 μm.

6. The microneedle patch of claim 1, wherein the needle body has a triangular pyramid shape, and the connecting portion has a single-side length of 180 μm to 200 μm at an end remote from the drug carrying portion.

7. The microneedle patch of claim 6, wherein adjacent two of the needle bodies in the same row or column are arranged in a staggered manner, so that two side edges of the adjacent two needle bodies, which are close to each other, are arranged in parallel.

8. The microneedle patch of claim 1, wherein the base is of the same composition as the connector;

9. The microneedle patch of claim 1, wherein the soluble polymer comprises one of polyvinyl alcohol, polycaprolactone, polyvinylpyrrolidone, hyaluronic acid, chitosan, carboxymethyl cellulose, fibroin.

10. The microneedle patch of claim 1, wherein the base is sodium hyaluronate;

and/or the connecting part is sodium hyaluronate.